Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jan 5;106(3):546–552. doi: 10.1038/bjc.2011.575

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2012 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The frequency of Tregs modulates the survival of MM patients. Kaplan–Meier curves displays the OS of groups of MM patients divided according the frequency of Treg. Patients with the percentages of CD4⁺CD25^highFOXP3⁺ Tregs below median value were classified to Treg low group whereas those of frequencies equal above median value to Treg high group. (A) In cumulative analysis, MM patients of Treg high group lived significantly lower as compared with those with lower Treg frequencies. In sub-analysis, the difference in survival was observed only in patients who were treated with MPT (B) while in patients treated with CTD followed by ASCT there was no difference in OS in groups of patients characterised by high or low Treg percentages (C).